Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
2,653 questions in 194 reviews · Gynaecology and Fertility
current versionsNo studies 531 · 20%Ungraded 76 · 2.9%Very low 826 · 31.1%Low 855 · 32.2%Moderate 341 · 12.9%High 24 · 0.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
GnRHa treatment vs no pretreatment or placebo before myomectomy (operative and postoperative outcomes Postoperative morbidity · women with uterine fibroids Preoperative medical therapy before surgery for uterine fibroids (2017) · Cochrane | OR 1.07 [0.43, 2.64] | 5 studies · 190 participants | Low |
GnRHa treatment vs no pretreatment or placebo before resection Duration of surgery (minutes) · women with uterine fibroids Preoperative medical therapy before surgery for uterine fibroids (2017) · Cochrane | no estimate extracted | 1 study · 39 participants | Low |
GnRHa treatment vs no pretreatment or placebo before resection Intraoperative blood loss (mL) · women with uterine fibroids Preoperative medical therapy before surgery for uterine fibroids (2017) · Cochrane | no estimate extracted | NR | No studies |
GnRHa treatment vs no pretreatment or placebo before resection Blood transfusions · women with uterine fibroids Preoperative medical therapy before surgery for uterine fibroids (2017) · Cochrane | no estimate extracted | NR | No studies |
GnRHa treatment vs no pretreatment or placebo before resection Postoperative morbidity · women with uterine fibroids Preoperative medical therapy before surgery for uterine fibroids (2017) · Cochrane | no estimate extracted | NR | No studies |
GnRHa treatment vs other medical therapies before any surgery Uterine volume (cm³) · women with uterine fibroids Preoperative medical therapy before surgery for uterine fibroids (2017) · Cochrane | no estimate extracted | NR | No studies |
GnRHa treatment vs other medical therapies before any surgery Fibroid volume (cm³) · women with uterine fibroids Preoperative medical therapy before surgery for uterine fibroids (2017) · Cochrane | no estimate extracted | 2 studies · 110 participants | Low |
GnRHa treatment vs placebo or no pretreatment (preoperative outcomes) Fibroid volume (mL) (preoperative) · women with uterine fibroids Preoperative medical therapy before surgery for uterine fibroids (2017) · Cochrane | no estimate extracted | 5 studies · 427 participants | Low |
GnRHa treatment vs other medical therapies before any surgery Preoperative haemoglobin (g/dL) · women with uterine fibroids Preoperative medical therapy before surgery for uterine fibroids (2017) · Cochrane | no estimate extracted | 1 study · 188 participants | Moderate |
GnRHa treatment vs other medical therapies before any surgery Preoperative bleeding: Reduction in bleeding to PBAC < 75 ulipristal acetate 5 mg · women with uterine fibroids Preoperative medical therapy before surgery for uterine fibroids (2017) · Cochrane | OR 0.71 [0.3, 1.68] | 1 study · 199 participants | Moderate |
GnRHa treatment vs other medical therapies before any surgery Preoperative bleeding: Reduction in bleeding to PBAC < 75 ulipristal acetate 10 mg · women with uterine fibroids Preoperative medical therapy before surgery for uterine fibroids (2017) · Cochrane | OR 0.39 [0.14, 1.06] | 1 study · 203 participants | Moderate |
GnRHa treatment vs other medical therapies before any surgery Adverse events (hot flushes) · women with uterine fibroids Preoperative medical therapy before surgery for uterine fibroids (2017) · Cochrane | OR 12.3 [4.04, 37.48] | 5 studies · 453 participants | Low |
SPRM vs placebo Uterine volume (cm³) · women with uterine fibroids Preoperative medical therapy before surgery for uterine fibroids (2017) · Cochrane | no estimate extracted | NR | No studies |
SPRM vs placebo Fibroid volume (cm³) · women with uterine fibroids Preoperative medical therapy before surgery for uterine fibroids (2017) · Cochrane | no estimate extracted | NR | No studies |
SPRM vs placebo Preoperative haemoglobin (g/dL) · women with uterine fibroids Preoperative medical therapy before surgery for uterine fibroids (2017) · Cochrane | no estimate extracted | 2 studies · 173 participants | High |
SPRM vs placebo Preoperative bleeding: (PBAC < 75) ulipristal acetate 5 mg · women with uterine fibroids Preoperative medical therapy before surgery for uterine fibroids (2017) · Cochrane | OR 41.41 [15.26, 112.38] | 1 study · 143 participants | Low |
SPRM vs placebo Preoperative bleeding: Reduction in menstrual bleeding (PBAC < 75) ulipristal acetate 10 mg · women with uterine fibroids Preoperative medical therapy before surgery for uterine fibroids (2017) · Cochrane | OR 78.83 [24.02, 258.74] | 1 study · 146 participants | Low |
SPRM vs placebo Preoperative bleeding: Change in menstrual blood loss from baseline to end of treatment · women with uterine fibroids Preoperative medical therapy before surgery for uterine fibroids (2017) · Cochrane | no estimate extracted | 1 study · 22 participants | Low |
GnRHa treatment vs placebo or no pretreatment (preoperative outcomes) Haemoglobin (g/dL) (preoperative) · women with uterine fibroids Preoperative medical therapy before surgery for uterine fibroids (2017) · Cochrane | no estimate extracted | 10 studies · 834 participants | Low |
SPRM vs placebo Adverse events · women with uterine fibroids Preoperative medical therapy before surgery for uterine fibroids (2017) · Cochrane | OR 0.05 [0, 1] | 1 study · 241 participants | Low |
GnRHa treatment vs placebo or no pretreatment (preoperative outcomes) Preoperative bleeding · women with uterine fibroids Preoperative medical therapy before surgery for uterine fibroids (2017) · Cochrane | no estimate extracted | NR | No studies |
GnRHa treatment vs placebo or no pretreatment (preoperative outcomes) Adverse events · women with uterine fibroids Preoperative medical therapy before surgery for uterine fibroids (2017) · Cochrane | OR 2.78 [1.77, 4.36] | 4 studies · 755 participants | Moderate |
GnRHa treatment vs no pretreatment or placebo before hysterectomy (operative and postoperative outcomes Duration of surgery (minutes) · women with uterine fibroids Preoperative medical therapy before surgery for uterine fibroids (2017) · Cochrane | no estimate extracted | 6 studies · 617 participants | Low |
GnRHa treatment vs no pretreatment or placebo before hysterectomy (operative and postoperative outcomes Intraoperative blood loss (mL) · women with uterine fibroids Preoperative medical therapy before surgery for uterine fibroids (2017) · Cochrane | no estimate extracted | 4 studies · 258 participants | Very low |
GnRHa treatment vs no pretreatment or placebo before hysterectomy (operative and postoperative outcomes Blood transfusions · women with uterine fibroids Preoperative medical therapy before surgery for uterine fibroids (2017) · Cochrane | OR 0.54 [0.29, 1.01] | 6 studies · 601 participants | Moderate |
GnRHa treatment vs no pretreatment or placebo before hysterectomy (operative and postoperative outcomes Postoperative morbidity · women with uterine fibroids Preoperative medical therapy before surgery for uterine fibroids (2017) · Cochrane | OR 0.54 [0.32, 0.91] | 7 studies · 772 participants | Low |
Coasting vs no coasting OHSS · Women undergoing assisted reproduction Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome (2017) · Cochrane | OR 0.11 [0.05, 0.24] | 2 studies · 207 participants | Low |
Coasting vs early unilateral follicular aspiration Miscarriage · Women undergoing assisted reproduction Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome (2017) · Cochrane | no estimate extracted | NR | No studies |
Coasting vs gonadotrophin‐releasing hormone antagonist OHSS · Women undergoing assisted reproduction Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome (2017) · Cochrane | no estimate extracted | 1 study · 190 participants | Very low |
Coasting vs gonadotrophin‐releasing hormone antagonist Live birth · Women undergoing assisted reproduction Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome (2017) · Cochrane | no estimate extracted | NR | No studies |
Coasting vs gonadotrophin‐releasing hormone antagonist Clinical Pregnancy · Women undergoing assisted reproduction Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome (2017) · Cochrane | OR 0.74 [0.42, 1.31] | 1 study · 190 participants | Low |
Coasting vs gonadotrophin‐releasing hormone antagonist Multiple pregnancy · Women undergoing assisted reproduction Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome (2017) · Cochrane | OR 0.84 [0.39, 1.8] | 1 study · 98 participants | Very low |
Coasting vs gonadotrophin‐releasing hormone antagonist Miscarriage · Women undergoing assisted reproduction Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome (2017) · Cochrane | no estimate extracted | NR | No studies |
Coasting vs follicle stimulating hormone administration at time of hCG OHSS · Women undergoing assisted reproduction Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome (2017) · Cochrane | OR 43.74 [2.54, 754.58] | 1 study · 102 participants | Very low |
Coasting vs follicle stimulating hormone administration at time of hCG Live birth · Women undergoing assisted reproduction Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome (2017) · Cochrane | no estimate extracted | NR | No studies |
Coasting vs follicle stimulating hormone administration at time of hCG Clinical Pregnancy · Women undergoing assisted reproduction Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome (2017) · Cochrane | OR 0.92 [0.43, 2.01] | 1 study · 102 participants | Low |
Coasting vs follicle stimulating hormone administration at time of hCG Multiple pregnancy · Women undergoing assisted reproduction Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome (2017) · Cochrane | no estimate extracted | NR | No studies |
Coasting vs no coasting Live birth · Women undergoing assisted reproduction Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome (2017) · Cochrane | OR 0.48 [0.14, 1.62] | 1 study · 68 participants | Very low |
Coasting vs follicle stimulating hormone administration at time of hCG Miscarriage · Women undergoing assisted reproduction Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome (2017) · Cochrane | no estimate extracted | NR | No studies |
Coasting vs cabergoline OHSS · Women undergoing assisted reproduction Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome (2017) · Cochrane | OR 1.98 [0.69, 5.68] | 2 studies · 120 participants | Very low |
Coasting vs cabergoline Live birth · Women undergoing assisted reproduction Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome (2017) · Cochrane | no estimate extracted | NR | No studies |
Coasting vs cabergoline Clinical pregnancy rate · Women undergoing assisted reproduction Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome (2017) · Cochrane | OR 0.38 [0.16, 0.88] | 2 studies · 120 participants | Very low |
Coasting vs cabergoline Multiple pregnancy · Women undergoing assisted reproduction Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome (2017) · Cochrane | no estimate extracted | NR | No studies |
Coasting vs cabergoline Miscarriage · Women undergoing assisted reproduction Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome (2017) · Cochrane | no estimate extracted | NR | No studies |
Coasting vs no coasting Clinical pregnancy · Women undergoing assisted reproduction Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome (2017) · Cochrane | OR 0.82 [0.46, 1.44] | 2 studies · 207 participants | Low |
Coasting vs no coasting Multiple pregnancy · Women undergoing assisted reproduction Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome (2017) · Cochrane | OR 0.31 [0.12, 0.81] | 1 study · 139 participants | Low |
Coasting vs no coasting Miscarriage · Women undergoing assisted reproduction Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome (2017) · Cochrane | OR 0.85 [0.25, 2.86] | 2 studies · 207 participants | Very low |
Coasting vs early unilateral follicular aspiration OHSS · Women undergoing assisted reproduction Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome (2017) · Cochrane | OR 0.98 [0.34, 2.85] | 2 studies · 83 participants | Very low |
Coasting vs early unilateral follicular aspiration Live birth · Women undergoing assisted reproduction Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome (2017) · Cochrane | no estimate extracted | NR | No studies |
Coasting vs early unilateral follicular aspiration Clinical Pregnancy · Women undergoing assisted reproduction Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome (2017) · Cochrane | OR 0.67 [0.25, 1.79] | 2 studies · 83 participants | Very low |